Viewing Study NCT03368859


Ignite Creation Date: 2025-12-24 @ 3:04 PM
Ignite Modification Date: 2026-02-20 @ 10:57 PM
Study NCT ID: NCT03368859
Status: TERMINATED
Last Update Posted: 2021-02-09
First Post: 2017-12-06
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
Sponsor: AbbVie
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cancer View
None colorectal cancer View
None ABT-165 View
None FOLFIRI View
None Bevacizumab View
None bowel cancer View
None metastatic colorectal cancer View
None metastatic colorectal View